Navigation Links
Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
Date:5/17/2012

BOSTON, May 17, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it will provide a live webcast of its Investor Day on Thursday, May 31, 2012, from 8:30 a.m. to 12:30 p.m. (EDT).

All interested parties are invited to listen as Chairman and Chief Executive Officer Josef von Rickenbach, Chief Financial Officer Jim Winschel and five additional members of the executive team provide a strategic overview of the Company's businesses through a series of presentations, followed by a question-and-answer session.

The live webcast will be accessible in the Investor Relations section of the Company's website at www.PAREXEL.com.  For those unable to listen to the live presentations, the event will be archived and available on the Company's website.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

 

CONTACT: Jill Baker, Corporate Vice President of Investor Relations
+1-781-434-4118

 

 

 


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
2. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
3. PAREXEL Announces Date of Third Quarter Fiscal Year 2012 Earnings Release and Conference Call
4. PAREXEL to Address New Regulatory Guidelines and Data Standards at DIA EuroMeeting
5. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
6. PAREXEL International to Present at Barclays Capital Healthcare Conference
7. PAREXEL International to Present at Cowen Healthcare Conference and Raymond James Investors Conference
8. PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives
9. PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
10. PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call
11. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/27/2017)... ... April 27, 2017 , ... Today, Jefferson Health in ... Colorado, announced an agreement to create the Jane and Leonard Korman Respiratory Institute ... and Leonard Korman Family Foundation. The collaboration leverages the strengths of each organization ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders ... of Thinksport’s award-winning sunscreen they’ve used the same scientific approach to solving smelly, ... deodorants flood the aisles that contain harmful chemicals that should be put nowhere ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. , the ... MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron Live! assembles ... helping organizations maximize the benefits of mobility in their operations securely. MobileIron ...
(Date:4/27/2017)... ... April 27, 2017 , ... Are you investing in ... in water-related accidents and drownings during the summer. While most of us assume this ... situations occur every day. Very few people are taking the time to learn how ...
Breaking Medicine News(10 mins):